

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee 1. Prime Health Services - Monroe, LLC d/b/a Monroe Hospital 2. 4011 South Monroe Medical Park Blvd. Bloomington, IN 47403	In accordance with letter dated July 14, 2016 3. License number: 13-32773-01 is amended in its entirety to read as follows:	4. Expiration Date: January 31, 2020 5. Docket No.: 030-38190 Reference No.:
--	---	---

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license	9. Authorized use
A. Any byproduct material permitted by 10 CFR 35.100 B. Any byproduct material permitted by 10 CFR 35.200	A. Any B. Any	A. As Needed B. As Needed	A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100. B. For use in imaging and localization studies permitted by 10 CFR 35.200.

CONDITIONS

10. Licensed material may be used or stored at the licensee's facilities located at:
 1. 4011 South Monroe Medical Park Blvd., Bloomington, Indiana, 47403
11. The Radiation Safety Officer (RSO) for this license is Robert T. Anger, Jr., M.S.
12. Licensed material shall only be used by, or under the supervision of:

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

13-32773-01

Docket or Reference Number

030-38190

Amendment No. 8

A. Individuals permitted to work as an authorized user in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)Material and Use

Douglas D. Geiger, M.D.	10 CFR 35.100 and 35.200.
Bruce N. Monson, M.D.	10 CFR 35.100 and 35.200.
George K. Wolfer, Jr., M.D.	10 CFR 35.100 and 35.200.
Mark A. Bisesi, M.D.	10 CFR 35.100 and 35.200.
Neal David Abdullah, M.D.	10 CFR 35.100 and 35.200.
Sean M. Flynn, M.D.	10 CFR 35.100 and 35.200.
Bharati R. Kharkar, M.D.	10 CFR 35.100 and 35.200.
David Y. Lee, M.D.	10 CFR 35.100 and 35.200.
Todd A. Winkler, M.D.	10 CFR 35.100 and 35.200.
Chris W. McGary, M.D.	10 CFR 35.100 and 35.200.
Jonathan Staser, M.D.	10 CFR 35.100 and 35.200.
John F. Alexander, M.D.	10 CFR 35.100 and 35.200.
Per Amundson, M.D.	10 CFR 35.100 and 35.200.
Gregory Sutliff, M.D.	10 CFR 35.100 and 35.200.
Jennifer Petersen-Goldspiel, M.D.	10 CFR 35.100 and 35.200.
Andrew D. Ferguson, M.D.	10 CFR 35.100.
Eric Williams, M.D.	10 CFR 35.200.
Phillip R. Doering, M.D.	10 CFR 35.100 and 35.200.
Charles M. Orr, M.D.	10 CFR 35.100 and 35.200.
Vijay P. Roy, M.D.	10 CFR 35.100 and 35.200.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

13-32773-01

Amendment No. 8

Docket or Reference Number

030-38190

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Application dated October 23, 2009 (ML093100642)
- B. Facsimile dated January 26, 2010 (ML100261857)
- C. Letter dated March 27, 2012 (ML12107A479)
- D. Letter received via facsimile on June 25, 2012 (ML12177A230)
- E. Letter dated February 4, 2015 (ML15042A244)
- F. Letter dated May 18, 2016 (ML16145A406)

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: October 12, 2016By: Vered A. ShafferVered Shaffer
Region 3